Skip to content

Prophylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior Capsulotomy

Prophylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior Capsulotomy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07729189
Enrollment
210
Registered
2026-07-27
Start date
2025-03-10
Completion date
2025-09-10
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capsule Opacification, Ocular Hypertension

Keywords

Posterior Capsule Opacification, Timolol Maleate, Intraocular Pressure, Posterior Capsulotomy, Neodymium-Doped Yttrium Aluminum Garnet Laser

Brief summary

This randomized controlled trial evaluated whether a single drop of 0.5% timolol maleate, administered before neodymium-doped yttrium aluminium garnet (Nd:YAG) laser posterior capsulotomy, reduced the rise in intraocular pressure compared with standard care alone. The study included adults aged 18-65 years who had developed posterior capsular opacification at least 3 months after cataract surgery and were scheduled to undergo Nd:YAG laser posterior capsulotomy. Participants were randomly assigned to receive either prophylactic topical timolol maleate or standard care without prophylactic timolol. Intraocular pressure was measured before the laser procedure and again 1 hour after the procedure by an ophthalmologist who was unaware of the assigned treatment. The study was based on the hypothesis that mean intraocular pressure 1 hour after posterior capsulotomy would be lower among participants who received prophylactic timolol maleate than among those who received standard care alone.

Interventions

One drop of 0.5% timolol maleate ophthalmic solution was administered topically immediately before Nd:YAG laser posterior capsulotomy.

DRUGNo intervention

No prophylactic intraocular pressure-lowering medication was administered before Nd:YAG laser posterior capsulotomy.

Sponsors

CMH Multan Institute of Medical Sciences
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 18-65 years * Male or female participants * Diagnosed with posterior capsule opacification after cataract surgery * Posterior capsule opacification present for at least 3 months * Scheduled to undergo Nd:YAG laser posterior capsulotomy

Exclusion criteria

* History or documented diagnosis of glaucoma * Baseline intraocular pressure greater than 21 mmHg before the procedure

Design outcomes

Primary

MeasureTime frameDescription
Mean Intraocular Pressure 1 Hour After Nd:YAG Laser Posterior Capsulotomy1 hour after Nd:YAG laser posterior capsulotomyIntraocular pressure was measured in millimetres of mercury using a Canon non-contact tonometer. The mean intraocular pressure measured 1 hour after Nd:YAG laser posterior capsulotomy was compared between participants who received one drop of 0.5% topical timolol maleate before the procedure and participants who received standard care without prophylactic timolol.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORIfrah Idress Lodhi

CMH Institute of Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026